These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 16230195

  • 1. Chronic community-acquired Acinetobacter pneumonia that responded slowly to rifampicin in the anti-tuberculous regime.
    Sharma A, Shariff M, Thukral SS, Shah A.
    J Infect; 2005 Oct; 51(3):e149-52. PubMed ID: 16230195
    [Abstract] [Full Text] [Related]

  • 2. Fulminant community-acquired pneumonia probably caused by Acinetobacter lwoffii.
    Toyoshima M, Chida K, Suda T.
    Respirology; 2010 Jul; 15(5):867-8. PubMed ID: 20546186
    [Abstract] [Full Text] [Related]

  • 3. [Nosocomial pneumonia caused by multiresistant Acinetobacter baumanii treated by colistin and rifampicin].
    Motaouakkil S, Charra B, Hachimi A, Benslama A.
    Ann Fr Anesth Reanim; 2006 May; 25(5):543-4. PubMed ID: 16488103
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model.
    Song JY, Cheong HJ, Lee J, Sung AK, Kim WJ.
    Int J Antimicrob Agents; 2009 Jan; 33(1):33-9. PubMed ID: 18835761
    [Abstract] [Full Text] [Related]

  • 5. Severe community-acquired Acinetobacter baumannii pneumonia: an emerging highly lethal infectious disease in the Asia-Pacific.
    Ong CW, Lye DC, Khoo KL, Chua GS, Yeoh SF, Leo YS, Tambyah PA, Chua AC.
    Respirology; 2009 Nov; 14(8):1200-5. PubMed ID: 19909464
    [Abstract] [Full Text] [Related]

  • 6. Community-acquired Acinetobacter baumannii pneumonia.
    Bachoumas K, Lebert C, Lacherade JC, Reignier J.
    Med Mal Infect; 2015 Aug; 45(8):337-9. PubMed ID: 26141128
    [No Abstract] [Full Text] [Related]

  • 7. Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam.
    Pachón-Ibáñez ME, Fernández-Cuenca F, Docobo-Pérez F, Pachón J, Pascual A.
    J Antimicrob Chemother; 2006 Sep; 58(3):689-92. PubMed ID: 16870647
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Bronchoalveolar interleukin-1 beta: a marker of bacterial burden in mechanically ventilated patients with community-acquired pneumonia.
    Wu CL, Lee YL, Chang KM, Chang GC, King SL, Chiang CD, Niederman MS.
    Crit Care Med; 2003 Mar; 31(3):812-7. PubMed ID: 12626989
    [Abstract] [Full Text] [Related]

  • 10. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections.
    Saballs M, Pujol M, Tubau F, Peña C, Montero A, Domínguez MA, Gudiol F, Ariza J.
    J Antimicrob Chemother; 2006 Sep; 58(3):697-700. PubMed ID: 16895941
    [Abstract] [Full Text] [Related]

  • 11. [Community-acquired Acinetobacter baumannii pneumonia].
    Salas Coronas J, Cabezas Fernández T, Alvarez-Ossorio García de Soria R, Díez García F.
    Rev Clin Esp; 2003 Jun; 203(6):284-6. PubMed ID: 12783714
    [Abstract] [Full Text] [Related]

  • 12. Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
    Song JY, Lee J, Heo JY, Noh JY, Kim WJ, Cheong HJ, Hwang IS.
    Int J Antimicrob Agents; 2008 Sep; 32(3):281-4. PubMed ID: 18650070
    [No Abstract] [Full Text] [Related]

  • 13. [Severe community-acquired pneumonia due to Acinetobacter baumannii].
    Tanaka M, Asada M, Kanda A, Okazaki K, Inomata S, Akiu N, Ebihara S.
    Nihon Kokyuki Gakkai Zasshi; 2011 Oct; 49(10):760-4. PubMed ID: 22117314
    [Abstract] [Full Text] [Related]

  • 14. Acinetobacter baumannii: an emerging multidrug-resistant threat.
    Gootz TD, Marra A.
    Expert Rev Anti Infect Ther; 2008 Jun; 6(3):309-25. PubMed ID: 18588496
    [Abstract] [Full Text] [Related]

  • 15. Therapeutic options for Acinetobacter baumannii infections.
    Vila J, Pachón J.
    Expert Opin Pharmacother; 2008 Mar; 9(4):587-99. PubMed ID: 18312160
    [Abstract] [Full Text] [Related]

  • 16. [A case of fulminant community-acquired Acinetobacter pneumonia in a healthy woman].
    Morioka H, Matsumoto S, Kojima E, Takada K, Shizu M, Okachi S.
    Nihon Kokyuki Gakkai Zasshi; 2011 Jan; 49(1):57-61. PubMed ID: 21384683
    [Abstract] [Full Text] [Related]

  • 17. Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model.
    Koomanachai P, Kim A, Nicolau DP.
    J Antimicrob Chemother; 2009 May; 63(5):982-7. PubMed ID: 19279050
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Intratracheal colistin sulfate for BALB/c mice with early pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
    Chiang SR, Chuang YC, Tang HJ, Chen CC, Chen CH, Lee NY, Chou CH, Ko WC.
    Crit Care Med; 2009 Sep; 37(9):2590-5. PubMed ID: 19623044
    [Abstract] [Full Text] [Related]

  • 20. Acinetobacter baumannii pneumonia: a case report and review of the literature.
    Iskandar SB, Guha B, Krishnaswamy G, Roy TM.
    Tenn Med; 2003 Sep; 96(9):419-22. PubMed ID: 14513529
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.